High doses of intravenous vitamin C may reduce arthritic pain.
Chronic inflammation is a hallmark symptom of rheumatoid arthritis, a notion further supported by clinical evidence that subjects with rheumatoid arthritis bear higher levels of inflammation-inducing reactive oxygen species (ROS) within the body.
Any number of ROS-scavenging ingredients, then, might alleviate inflammation in those with rheumatoid arthritis. But researchers at the Riordan Clinic in Wichita, Kansas are looking at rheumatoid arthritis and vitamin C (ascorbic acid). Vitamin C isn’t just an ROS scavenger; it aids in collagen formation, and clinical trials indicate that rheumatoid arthritis sufferers often have vitamin C deficiency and low levels of vitamin C in their synovial fluid, the primary lubricant of human joints. All of this led Riordan Clinic researchers to investigate the potential for relieving rheumatoid arthritis pain with very high vitamin C doses.
In a pilot study on 11 rheumatoid arthritis patients, subjects were assigned to intravenous doses of vitamin C ranging from 7.5 g to 50 g. The primary endpoint was C-reactive protein (CRP), a marker of inflammation that dropped by an average of 44% in the nine subjects who experienced decreases.
Riordan Clinic researchers are hopeful that future arthritis research will focus on vitamin C doses and specific levels of proinflammatory cytokines.
Magnesium L-threonate, Magtein, earns novel food authorization in the European Union
December 19th 2024According to the announcement, the authorization is also exclusive to AIDP and its partner company and licensee, ThreoTech, meaning that they are the only parties that can market magnesium L-threonate in the EU for a period of five years.